We estimated age-standardized cancer incidence (2010–2019) and mortality rates (2010–2022) in the United States to investigate whether cancer rates have increased at younger ages. Fourteen cancers had ...

We identified mutation-harboring precancerous cells that emerge via oligodendrocyte progenitor cell fate specification and contribute to the evolution of GBM with intratumoral molecular heterogeneity.

AbstractRAS inhibition has the potential to transform cancer treatment for many patients. The landscape of RAS inhibitor therapies is rapidly evolving, with two mutant-selective KRAS inhibitors now ...

Cancers generate complex immunologic stressors that can alter the myelopoietic output, leading to the formation of heterogeneous myeloid cell populations [i.e., tumor-associated macrophages (TAM) and ...

Abstract. Radiomics, the extraction of quantitative data from images, holds promise for noninvasively characterizing tumor phenotypes. Tools like LIFEx have improved the accessibility, transparency, ...

Abstract. The integration of artificial intelligence (AI) in cancer research has significantly advanced radiology, pathology, and multimodal approaches, offering unprecedented capabilities in image ...

Chimeric antigen receptor (CAR) T-cell therapy has improved outcomes for patients with chemotherapy-resistant B-cell malignancies. However, CAR T-cell treatment of patients with solid cancers has been ...

Accurate preoperative assessment of lymph node metastasis (LNM) and overall survival (OS) status is essential for patients with locally advanced gastric cancer receiving neoadjuvant chemotherapy, ...

Abstract. Conducting phase I trials is particularly challenging when dealing with late-onset dose-limiting toxicity (DLT) or when patient accrual is rapid relative to the DLT assessment window. In ...

Summary. Antibody–drug conjugates are an emerging treatment of non–small cell lung cancer. Some do not require biomarkers, whereas others require mutations and/or protein expression. New diagnostic ...

Doxorubicin-naïve patients with metastatic soft-tissue sarcoma were enrolled in this phase Ib study. Every 21 days, subjects received ribociclib daily for 7 days followed by 3 days of no treatment ...

AbstractPurpose:. Death receptor (DR)–targeted therapies offer a promising tumor cell–specific therapeutic strategy for highly malignant brain tumors, such as glioblastoma (GBM). However, whether ...